The lancet oncology
-
The lancet oncology · Aug 2021
Meta AnalysisTrastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. ⋯ Cancer Research UK, UK Medical Research Council.
-
The lancet oncology · May 2021
Meta AnalysisChemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of locally advanced head and neck cancer. However, the relative efficacy of these treatments is unknown. We aimed to determine whether one treatment was superior to the other. ⋯ French Institut National du Cancer, French Ligue Nationale Contre le Cancer, and Fondation ARC.
-
The lancet oncology · Apr 2021
Meta AnalysisAntihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials. ⋯ British Heart Foundation, National Institute for Health Research, Oxford Martin School.
-
The lancet oncology · Apr 2021
Meta AnalysisAntihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in a large individual patient data meta-analysis of randomised clinical trials. ⋯ British Heart Foundation, National Institute for Health Research, Oxford Martin School.
-
The lancet oncology · Mar 2021
Meta AnalysisIntermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials. We sought to comprehensively assess aggregate trial-level performance of commonly reported intermediate clinical endpoints across all randomised trials in localised prostate cancer. ⋯ Prostate Cancer Foundation and National Institutes of Health.